CSIMarket Company Name, Ticker, Suppliers, else..
 
Avalo Therapeutics Inc   (NASDAQ: AVTX)
 
Price: $19.2300 $0.23 1.211%
Day's High: $19.579999923706055 Week Perf: -0.57 %
Day's Low: $ 18.80 30 Day Perf: 2.83 %
Volume (M): 633,217 52 Wk High: $ 24.27
Volume (M$): $ 0 52 Wk Avg: $16.36
Open: $18.81 52 Wk Low: $9.54



 Market Capitalization (Millions $) 387
 Shares Outstanding (Millions) 20
 Employees 33
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -85
 Cash Flow (TTM) (Millions $) -100
 Capital Exp. (TTM) (Millions $) 0

Business Description


Avalo Therapeutics Inc is a pharmaceutical company that focuses on developing novel cancer therapies. The company's primary aim is to develop treatments that can harness the body's immune system to fight against cancer, particularly in patients whose tumors exhibit resistance to existing therapies. Avalo Therapeutics is dedicated to advancing innovative immunotherapy approaches and discovering new targets for effective cancer treatment.


   Company Address: 1500 Liberty Ridge Drive, Suite 321 Wayne 19087 PA
   Company Phone Number: 522-8707   Stock Exchange / Ticker: NASDAQ AVTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY        0.36% 
PTCT   -1.13%    
REGN        4.22% 
TEVA   -0.22%    
VRTX        0.82% 
VTRS        3.3% 
• View Complete Report
   



Clinical Study

Navigating the Rocky Road of Innovation Avalo Therapeutics Ambitious Pursuit of Advanced IL-1 Therapeutics in Hidrad...

Published Wed, Oct 29 2025 12:43 PM UTC

The therapeutic landscape for hidradenitis suppurativa (HS), a debilitating chronic inflammatory skin condition, has been markedly stagnant until recent advances in biotechnology. At the forefront of this change is Avalo Therapeutics, Inc., a clinical stage biotechnology firm that is striving to carve out a niche within a competitive market through its aggressive developmen...
Clinical Study

Breaking Ground Avalos AVTX-009 Begins Phase 2 Journey, Offering New Hope for Hidradenitis Suppurativa Patie...

Published Tue, Oct 8 2024 11:00 AM UTC

: Avalo Therapeutics, Inc. has initiated its Phase 2 LOTUS trial, marking a significant advancement in the development of AVTX-009, a humanized monoclonal antibody aimed at treating hidradenitis suppurativa (HS). This article delves into the implications of AVTX-009 s mechanism of action, its potential benefits for patients with HS, and the significance of this milestone i...
Clinical Study

Avalo Therapeutics Sets the Stage for Breakthrough HS Treatment with Active IND for AVTX-009

Published Tue, Jul 9 2024 11:00 AM UTC

In a remarkable stride towards innovative treatment options for Hidradenitis Suppurativa (HS), Avalo Therapeutics, Inc. recently announced the active status of its Investigational New Drug (IND) application for AVTX-009. This development allows the biotechnology company to initiate its pivotal Phase 2 LOTUS clinical trial, aimed at exploring the efficacy of their anti-IL-1 m...
Shares

Avalo Therapeutics Welcomes Paul Varki as Chief Legal Officer, Shareholders Rejoice

Published Mon, Jun 24 2024 8:01 PM UTC


In a strategic move to further strengthen its leadership team, Avalo Therapeutics, Inc. (Nasdaq: AVTX) proudly announced the appointment of Paul Varki as its new Chief Legal Officer. Varki brings with him a wealth of experience and expertise in the legal field, positioning him as a valuable asset to the company s continued growth and success.
The appointment of Vark...
Merger and Acquisition

Avalo Therapeutics Sets New Standards in Cancer Therapy with Strong 2023 Results and Exciting Business Updates

Published Fri, Mar 29 2024 8:01 PM UTC

Breaking News: Avalo Therapeutics Reports Strong 2023 Results and Exciting Business Updates
WAYNE, Pa. and ROCKVILLE, Md., March 29, 2024 - Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading biotechnology company specializing in novel cancer therapies, announced its remarkable business updates and year-end financial results for 2023. With their focus on developing target...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 6,553.49
Price to Sales (Expected) -
Price to Book 5.66
PEG (TTM) -

Financial Strength Current
Quick Ratio 7.08
Working Capital Ratio 7.66
Leverage Ratio (MRQ) 0.46
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -5.84 $
Revenues (TTM) 0 $
Cash Flow (TTM) -
Cash 4.09 $
Book Value 3.4 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -2,567,879
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.